All patients were evaluable for toxicity and 34 for response. The overall response rate was 67 % (CR: 26 % ; PR: 41 % ; intention-to-treat analysis) (95 % CI: 53.0–84.2 % ). After a median follow-up period of 15 months, the median survival time was 15 months, the median time to tumor progression 8.3 months and the 1-year survival rate 53.8 % . Grade 3/4 neutropenia occurred in 39 % and 36 % of patients receiving EP and PP regimens, respectively. The incidence of febrile neutropenia was 5 % and 3 % for EP and PP regimens, respectively. Other hematologic and non-hematologic toxicities were mild, with the exception of esophagitis occuring in 36 % of patients during and/or immediately after radiotherapy.
Consolidation therapy with PP after sequential EP and thoracic radiotherapy is feasible and well-tolerated; however, the efficacy results are comparable with those previously obtained in the same patients’ population using a combination of EP and TRT.
O Lung Cancer |
O Lung Cancer, Volume 41, Supplement 2, August 2003, Page S24 Kaoru Kubota, Yutaka Nishiwaki, Takahiko Sugiura, Kazumasa Noda, Kiyoshi Mori, Masaaki Kawahara, Shunichi Negoro, Koshiro Watanabe, Tomohide Tamura, Nagahiro Saijo Purchase PDF (176 K) |
P Lung Cancer |
P Lung Cancer, Volume 41, Supplement 2, August 2003, Page S105 Ji-Youn Han, Kwan Ho Cho, Dae Ho Lee, Seong Min Yoon, Hyae Young Kim, Sung Young Lee, Han Jin Yoo, Jin Soo Lee Purchase PDF (176 K) |
View More Related Articles |